Cargando…
Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen
INTRODUCTION: Aripiprazole once-monthly is a long-acting intramuscular injectable formulation of aripiprazole. The starting dose can be administered by following one of two regimens: • One injection start: On the day of initiation, administer one injection of 400 mg Aripiprazole once monthly and con...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567763/ http://dx.doi.org/10.1192/j.eurpsy.2022.2037 |
_version_ | 1784809481514778624 |
---|---|
author | Romero Guillena, S.L. Plasencia Garcia De Diego, B.O. Gotor Sanchez-Luengo, F. Gómez González, J. |
author_facet | Romero Guillena, S.L. Plasencia Garcia De Diego, B.O. Gotor Sanchez-Luengo, F. Gómez González, J. |
author_sort | Romero Guillena, S.L. |
collection | PubMed |
description | INTRODUCTION: Aripiprazole once-monthly is a long-acting intramuscular injectable formulation of aripiprazole. The starting dose can be administered by following one of two regimens: • One injection start: On the day of initiation, administer one injection of 400 mg Aripiprazole once monthly and continue treatment with 10 mg to 20 mg oral aripiprazole per day for 14 consecutive days • Two injection start (New regimen): On the day of initiation, administer two separate injections of 400 mg Aripiprazole once monthly at separate injection sites, along with one 20 mg dose of oral aripiprazole. OBJECTIVES: To assess the effectiveness and tolerability of Aripiprazole long-acting injectable (ALAI) in patients with schizophrenia. The starting dose was administered following the two injection start regimen METHODS: Sample:10 patients with schizophrenia (DSM 5 criteria) who started treatment with ALAI. The starting dose was administered following the two injection start regimen. On a tri-monthly basis, the following evaluations were performed during a follow-up period of 6 months: The Clinical Global Impression-Schizophrenia scale (CGI-SCH), treatment adherence, the number of hospitalizations and Side effects reported RESULTS: Mean variations from baseline scores at 6 months was (-1.1 ±0.89) on the GCI-SCH. The percentage of patients who remained free of admissions at the end of the 6 months was 90%. The rate of adherence to treatment after 6 months was 80%. The most frequent side effect was transient mild insomnia (20%) . CONCLUSIONS: Aripiprazole long-acting injectable (The starting dose was administered following the two injection start regimen) is effective, safe and well tolerated in clinical practice conditions DISCLOSURE: No significant relationships. |
format | Online Article Text |
id | pubmed-9567763 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95677632022-10-17 Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen Romero Guillena, S.L. Plasencia Garcia De Diego, B.O. Gotor Sanchez-Luengo, F. Gómez González, J. Eur Psychiatry Abstract INTRODUCTION: Aripiprazole once-monthly is a long-acting intramuscular injectable formulation of aripiprazole. The starting dose can be administered by following one of two regimens: • One injection start: On the day of initiation, administer one injection of 400 mg Aripiprazole once monthly and continue treatment with 10 mg to 20 mg oral aripiprazole per day for 14 consecutive days • Two injection start (New regimen): On the day of initiation, administer two separate injections of 400 mg Aripiprazole once monthly at separate injection sites, along with one 20 mg dose of oral aripiprazole. OBJECTIVES: To assess the effectiveness and tolerability of Aripiprazole long-acting injectable (ALAI) in patients with schizophrenia. The starting dose was administered following the two injection start regimen METHODS: Sample:10 patients with schizophrenia (DSM 5 criteria) who started treatment with ALAI. The starting dose was administered following the two injection start regimen. On a tri-monthly basis, the following evaluations were performed during a follow-up period of 6 months: The Clinical Global Impression-Schizophrenia scale (CGI-SCH), treatment adherence, the number of hospitalizations and Side effects reported RESULTS: Mean variations from baseline scores at 6 months was (-1.1 ±0.89) on the GCI-SCH. The percentage of patients who remained free of admissions at the end of the 6 months was 90%. The rate of adherence to treatment after 6 months was 80%. The most frequent side effect was transient mild insomnia (20%) . CONCLUSIONS: Aripiprazole long-acting injectable (The starting dose was administered following the two injection start regimen) is effective, safe and well tolerated in clinical practice conditions DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9567763/ http://dx.doi.org/10.1192/j.eurpsy.2022.2037 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Romero Guillena, S.L. Plasencia Garcia De Diego, B.O. Gotor Sanchez-Luengo, F. Gómez González, J. Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen |
title | Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen |
title_full | Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen |
title_fullStr | Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen |
title_full_unstemmed | Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen |
title_short | Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen |
title_sort | efficacy and tolerability aripiprazole once-monthly long-acting injectable in schizophrenia. two-injection start regimen |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567763/ http://dx.doi.org/10.1192/j.eurpsy.2022.2037 |
work_keys_str_mv | AT romeroguillenasl efficacyandtolerabilityaripiprazoleoncemonthlylongactinginjectableinschizophreniatwoinjectionstartregimen AT plasenciagarciadediegobo efficacyandtolerabilityaripiprazoleoncemonthlylongactinginjectableinschizophreniatwoinjectionstartregimen AT gotorsanchezluengof efficacyandtolerabilityaripiprazoleoncemonthlylongactinginjectableinschizophreniatwoinjectionstartregimen AT gomezgonzalezj efficacyandtolerabilityaripiprazoleoncemonthlylongactinginjectableinschizophreniatwoinjectionstartregimen |